321 related articles for article (PubMed ID: 33226355)
1. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
[TBL] [Abstract][Full Text] [Related]
2. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
[TBL] [Abstract][Full Text] [Related]
6. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
deBruyn JC; Huynh HQ; Griffiths AM; Jacobson K; Mack D; Deslandres C; El-Matary W; Otley AR; Church PC; Lawrence S; Wine E; Sherlock M; Critch J; Benchimol EI; Jantchou P; Rashid M; Carroll MW; Bax K; Ricciuto A; Carman N; Walters TD;
Am J Gastroenterol; 2024 Mar; 119(3):565-575. PubMed ID: 37787642
[TBL] [Abstract][Full Text] [Related]
10. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
Varma P; Paul E; Huang C; Headon B; Sparrow MP
Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.
Molander P; Färkkilä M; Kemppainen H; Blomster T; Jussila A; Mustonen H; Sipponen T
Scand J Gastroenterol; 2017 Mar; 52(3):284-290. PubMed ID: 27806638
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
14. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Chanchlani N; Lin S; Bewshea C; Hamilton B; Thomas A; Smith R; Roberts C; Bishara M; Nice R; Lees CW; Sebastian S; Irving PM; Russell RK; McDonald TJ; Goodhand JR; Ahmad T; Kennedy NA;
Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):521-538. PubMed ID: 38640937
[TBL] [Abstract][Full Text] [Related]
16. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
Kapizioni C; Desoki R; Lam D; Balendran K; Al-Sulais E; Subramanian S; Rimmer JE; De La Revilla Negro J; Pavey H; Pele L; Brooks J; Moran GW; Irving PM; Limdi JK; Lamb CA; ; Parkes M; Raine T
J Crohns Colitis; 2024 Jun; 18(6):790-800. PubMed ID: 38041850
[TBL] [Abstract][Full Text] [Related]
17. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.
Kotze PG; Yamamoto T; Danese S; Suzuki Y; Teixeira FV; de Albuquerque IC; Saad-Hossne R; de Barcelos IF; da Silva RN; da Silva Kotze LM; Olandoski M; Sacchi M; Yamada A; Takeuchi K; Spinelli A
J Crohns Colitis; 2015 Jul; 9(7):541-7. PubMed ID: 25820017
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
[TBL] [Abstract][Full Text] [Related]
19. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae.
Maas L; Gao R; Cusumano V; Spartz E; Chowdhury R; Krishna M; Lazarev M; Melia J; Selaru F; Sharma S; Limketkai B; Parian A
Dig Dis Sci; 2023 Oct; 68(10):3994-4000. PubMed ID: 37540392
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
Christensen KR; Steenholdt C; Brynskov J
Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]